Avalo Q2 FY26 net loss widens to $36.4 million; R&D expense rises 66.1% to $23.4 million

Reuters2026/08/06 11:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Avalo Therapeutics posted a Q2 net loss of $36.4 million, widening from $20.8 million a year earlier.
R&D expense rose to $23.4 million from $14.1 million, due to a $10 million abdakibart development milestone and HS program costs.
G&A expense climbed to $8.1 million from $5.2 million, mainly on higher stock-based compensation.
Cash, cash equivalents and investments totaled $472.2 million at June 30, expected to fund operations into 2029.
Plans call for a registrational Phase 3 program of abdakibart in hidradenitis suppurativa in H1 2027; AVTX-010 IND filing targeted in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Avalo Q2 FY26 net loss widens to $36.4 million; R&D expense rises 66.1% to $23.4 million

You may also like

Crypto prices